Recent Updates
Recently added Catalysts
DYN

Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases

Wednesday, April 3, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
13%
average across 7 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Zeleciment Rostudirsen
Phase 3 · Duchenne Muscular Dystrophy (DMD)

Full Press Release Details

Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases.
ShareAdd on Google
Tags: DYN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 3, 2019

Biotech snapshot

Cash runway
$898M liquidity · $43M/mo burn
~20 mo
Low dilution risk
Lead asset
Zeleciment RostudirsenPhase 3
Duchenne Muscular Dystrophy (DMD) →

Catalyst track record

+65%
best trade around DYN's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for DYN.

See every catalyst's timing & PoA →